In an issue of The Lancet, an international research team in which VHIO participated, reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumours were surgically removed.
To find out more about the results from this present NeoAdjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) pivotal study visit The Lancet.
For more information about VHIO´s participation please contact Amanda Wren, Communication Manager directly: Tel. +34 934893021, Email: awren@vhio.net.
